glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.53432/2078-4104-2023-22-1-85-91glaucoma-438Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОценка эффективности и переносимости фиксированной комбинации бринзоламида 1% и тимолола 0,5% в лечении первичной открытоугольной глаукомыEvaluation of the efficacy and tolerability of 1% brinzolamide and 0.5% timolol fixed combination in the treatment of primary open-angle glaucomaСидороваА. В.SidorovaA. V.

Зав. отделением хирургического лечения глаукомы.

127486, Российская Федерация, Москва, Бескудниковский бульвар, 59А

Head of the Glaucoma Surgery Department.

59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

СтаростинаА. В.StarostinaA. V.

Старостина Анна Владимировна - к.м.н., научный сотрудник отдела хирургического лечения глаукомы.

127486, Российская Федерация, Москва, Бескудниковский бульвар, 59А

Cand. Sci. (Med.), researcher at the Glaucoma Surgery Department.

59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

anna.mntk@mail.ruБурлаковК. С.BurlakovK. S.

Клинический ординатор.

127486, Российская Федерация, Москва, Бескудниковский бульвар, 59А

Clinical resident.

59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

КокаеваЕ. А.KokaevaE. A.

Клинический ординатор.

127486, Российская Федерация, Москва, Бескудниковский бульвар, 59А

Clinical resident.

59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

БулдаковИ. А.BuldakovI. A.

Клинический ординатор.

127486, Российская Федерация, Москва, Бескудниковский бульвар, 59А

Clinical resident.

59A Beskudnikovsky Blvd., Moscow, Russian Federation, 127486

ФГАУ «НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова» Минздрава РФРоссияS.N. Fedorov National Medical Research Center "MNTK "Eye Microsurgery"Russian Federation2023230320232218591Copyright © Сидорова А.В., Старостина А.В., Бурлаков К.С., Кокаева Е.А., Булдаков И.А., 20232023Сидорова А.В., Старостина А.В., Бурлаков К.С., Кокаева Е.А., Булдаков И.А.Sidorova A.V., Starostina A.V., Burlakov K.S., Kokaeva E.A., Buldakov I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/438ЦЕЛЬ

ЦЕЛЬ. Оценка влияния перехода пациентов, нуждающихся в фиксированной комбинации гипотензивных капель, с глазных капель бринзоламид 1% и тимолол 0,5% (Азарга, Alcon Laboratories Inc, США) на фиксированную комбинацию бринзоламида 1% и тимолола 0,5% (Бринарга, Sentiss Pharma, Индия), изучение потенциального влияния на переносимость и комплаентность, сравнение терапевтического эффекта двух комбинаций.

МЕТОДЫ

МЕТОДЫ. Пациенты были переведены с комбинации глазных капель бринзоламида 1% и тимолола 0,5% (Азарга) на фиксированную комбинацию бринзоламида 1% и тимолола 0,5% (Бринарга). Был использован опросник для выявления возможных побочных эффектов, а также проведены инструментальные методы исследования.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ. Тридцать шесть пациентов (14 мужчин и 22 женщины в возрасте 41–89 лет) были опрошены и обследованы на контрольных приемах. Сравнение тяжести и постоянства побочных эффектов двух типов фиксированных комбинаций показало, что оба препарата можно считать безопасными и эффективными консервативными методами лечения глаукомы.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ. Фиксированная комбинация бринзоламида 1% и тимолола 0,5% (Бринарга) по эффективности снижения ВГД соответствует комбинации бринзоламида 1% и тимолола 0,5% (Азарга). Выраженных побочных реакций выявлено не было, они соответствовали таковым до смены терапии. Таким образом, комбинацию бринзоламид 1% и тимолол 0,5% (Бринарга) можно рассматривать как эффективное и безопасное средство для лечения глаукомы.

PURPOSE

PURPOSE. To evaluate the effect of swtiching patients requiring a fixed combination of hypotensive eye drops from brinzolamide 1%/timolol 0.5% Azarga (Alcon Laboratories Inc, USA) to brinzolamide 1%/timolol 0.5% Brinarga (Sentiss Pharma, India), as well as to study the potential impact on tolerability and compliance, and compare the therapeutic effect of these two combinations.

METHODS

METHODS. Patients were switched from brinzolamide 1%/timolol 0.5% fixed combination eye drops Azarga to brinzolamide 1%/timolol 0.5% fixed combination eye drops Brinarga. In addition to the conventional instrumental examination methods, a questionnaire was used to identify potential side effects.

RESULTS

RESULTS. Thirty-six patients (14 men and 22 women aged 41–89 years) were interviewed and examined in control appointments. A comparison of the severity and persistence of side effects of two types of fixed combination eye drops showed that brinzolamide 1%/timolol 0.5% (Brinarga) and brinzolamide 1%/timolol 0.5% (Azarga) can be considered as safe and effective conservative methods of glaucoma treatment.

CONCLUSION

CONCLUSION. The fixed combination of brinzolamide 1%/timolol 0.5% (Brinarga) is comparable to brinzolamide 1%/timolol 0.5% (Azarga) in terms of the IOP reduction effectiveness. No pronounced adverse reactions were detected, which was comparable to the status before the change of therapy. Thus, the combination of brinzolamide 1%/timolol 0.5% (Brinarga) can be considered as an effective and safe treatment option for glaucoma patients.

глаукомабринзоламидтимололБринаргаАзаргаglaucomabrinzolamide 1%timolol 0.5%BrinargaAzargaReferencesGBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021; 9(2):e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7.GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021; 9(2):e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7.Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Investigative Ophtalmology & Visual Science 2003; 44(9):3783-3789. https://doi.org/10.1167/iovs.03-0077Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Investigative Ophtalmology & Visual Science 2003; 44(9):3783-3789. https://doi.org/10.1167/iovs.03-0077Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, Jansonius NM. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology 2010; 117(9):1705-1712. https://doi.org/10.1016/j.ophtha.2010.01.034Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, Jansonius NM. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology 2010; 117(9):1705-1712. https://doi.org/10.1016/j.ophtha.2010.01.034Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6):701-713; discussion 829-830. https://doi.org/10.1001/archopht.120.6.701.Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6):701-713; discussion 829-830. https://doi.org/10.1001/archopht.120.6.701.Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982; 93:232-237. https://doi.org/10.1016/0002-9394(82)90419-6Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982; 93:232-237. https://doi.org/10.1016/0002-9394(82)90419-6Costagliola C, Omo R, Romano R, et al. Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009; 10:2859-2870. https://doi.org/10.1517/14656560903300129.Costagliola C, Omo R, Romano R, et al. Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009; 10:2859-2870. https://doi.org/10.1517/14656560903300129.Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12:393-398. https://doi.org/10.1097/00061198-200310000-00001Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12:393-398. https://doi.org/10.1097/00061198-200310000-00001Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-868. https://doi.org/10.1016/j.ophtha.2004.12.026Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-868. https://doi.org/10.1016/j.ophtha.2004.12.026Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once daily and adjunctive medication use. Am J Ophthalmology 2007; 144:533-540. https://doi.org/10.1016/j.ajo.2007.06.012Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once daily and adjunctive medication use. Am J Ophthalmology 2007; 144:533-540. https://doi.org/10.1016/j.ajo.2007.06.012Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15:132-135. https://doi.org/10.1097/00055735-200404000-00013Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15:132-135. https://doi.org/10.1097/00055735-200404000-00013Negri L, Ferreras A, Iester M. Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. J Ophthalmol 2019; 2019:4146124. https://doi.org/10.1155/2019/4146124Negri L, Ferreras A, Iester M. Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. J Ophthalmol 2019; 2019:4146124. https://doi.org/10.1155/2019/4146124Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44(2):141-145. https://doi.org/10.1016/s0039-6257(99)00111-3.Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44(2):141-145. https://doi.org/10.1016/s0039-6257(99)00111-3.Barnebey H., Kwok S.Y. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clinical therapeutics 2000; 22(10):1204-1212. https://doi.org/10.1016/s0149-2918(00)83063-5.Barnebey H., Kwok S.Y. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clinical therapeutics 2000; 22(10):1204-1212. https://doi.org/10.1016/s0149-2918(00)83063-5.Курышева Н.И. Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 1. Офтальмология 2020; 17(3s):542-549. https://doi.org/10.18008/1816-5095-2020-3S-542-549Kurysheva N.I. Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part I. Ophthalmology in Russia 2020;17(3s):542-549. https://doi.org/10.18008/1816-5095-2020-3S-542-549John H., Liu et al. Noctural IOP-lowering Effect of Brinzolamide versus Timolol. Ophthalmology 2009; 116(3):449-454. https://doi.org/10.1016/j.ophtha.2008.09.054John H., Liu et al. Noctural IOP-lowering Effect of Brinzolamide versus Timolol. Ophthalmology 2009; 116(3):449-454. https://doi.org/10.1016/j.ophtha.2008.09.054Национальное руководство по глаукоме для практикующих врачей. Под ред. Е.А. Егорова, В.П. Еричева. М: ГЭОТАР-Медиа 2019; 384.National glaucoma guidelines for practitioners. Edited by Egorov E.A., Erichev V.P. Moscow, Geotar-Media Publ., 2019. 384 p.Kaback M, Scoper SV, Arzeno G, James JE, Hua SY, Salem C, Dickerson JE, Landry TA, Bergamini MV; Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008; 115(10):1728-34, 1734.e1-2. https:doi.org/10.1016/j.ophtha.2008.04.011Kaback M, Scoper SV, Arzeno G, James JE, Hua SY, Salem C, Dickerson JE, Landry TA, Bergamini MV; Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008; 115(10):1728-34, 1734.e1-2. https:doi.org/10.1016/j.ophtha.2008.04.011Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011; 5:291-298. https:doi.org/10.2147/OPTH.S16355Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011; 5:291-298. https:doi.org/10.2147/OPTH.S16355Sezgin Akçay Bİ, Güney E, Bozkurt KT, Unlü C, Akçali G. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2013; 29(10):882-886. https://doi.org/10.1089/jop.2013.0102Sezgin Akçay Bİ, Güney E, Bozkurt KT, Unlü C, Akçali G. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2013; 29(10):882-886. https://doi.org/10.1089/jop.2013.0102

The authors declare that there are no conflicts of interest present.